Peptide-Drug Conjugates: A New Hope for Cancer Management

Chavda, Vivek P.; Solanki, Hetvi K.; Davidson, Majid; Bojarska, Joanna; Apostolopoulos, Vasso

doi:10.3390/molecules27217232

Cited by 40 publications

(31 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another approach that can be used in HCC patients is local ablation 205 . Local ablative treatments are a less intrusive form of surgery that can be used in patients diagnosed with early stage disease 206 . Furthermore, it can be used in management of various disease involving methods such as percutaneous ethanol injection, radiofrequency, and laser ablation 207 .…”

Section: Variations In Hcc Treatment and Interventionmentioning

confidence: 99%

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

et al. 2023

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. The incidence of HCC is affected by genetic and non‐genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT‐rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6‐phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E‐cadherin, have been shown to contribute to the occurrence of HCC. Non‐genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non‐alcoholic fatty liver disease (NAFLD), increase the risk of HCC.Recent FindingsThe severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non‐minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non‐Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC.ConclusionAssessment and treatment of HCC must be consistent using evidence‐based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.

show abstract

Section: Variations In Hcc Treatment and Interventionmentioning

confidence: 99%

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Also, doxorubicin along with silica nanoparticles and graphene dots can be used for tumor-targeted therapy as well as fluorescent imaging [71]. Apart from this, technologies such as dendrimers, liposomes, polymeric nanoparticle micelles, and solid lipid nanoparticles can be utilized for the delivery of chemotherapeutic drugs [72]. Other inorganic-based nanotheranostics include MoS2 nanosheets, single walled carbon nanotubes, and tungsten sulfide [54].…”

Section: Chemotherapymentioning

confidence: 99%

Current status of Cancer Nanotheranostics: Emerging strategies for cancer management

Chavda¹,

Khadela²,

Shah³

et al. 2023

Nanotheranostics

View full text Add to dashboard Cite

Cancer diagnosis and management have been a slow-evolving area in medical science. Conventional therapies have by far proved to have various limitations. Also, the concept of immunotherapy which was thought to revolutionize the management of cancer has presented its range of drawbacks. To overcome these limitations nanoparticulate-derived diagnostic and therapeutic strategies are emerging. These nanomaterials are to be explored as they serve as a prospect for cancer theranostics. Nanoparticles have a significant yet unclear role in screening as well as therapy of cancer. However, nanogels and Photodynamic therapy is one such approach to be developed in cancer theranostics. Photoactive cancer theranostics is a vivid area that might prove to help manage cancer. Also, the utilization of the quantum dots as a diagnostic tool and to selectively kill cancer cells, especially in CNS tumors. Additionally, the redox-sensitive micelles targeting the tumor microenvironment of the cancer are also an important theranostic tool. This review focuses on exploring various agents that are currently being studied or can further be studied as cancer theranostics.

show abstract

“…These advantages recently led to the authorisation of three PDCs for clinical use in cancer: vipivotide tetraxetan, melphalan flufenamide and a somatostatin derivative, 177 Lu-DOTATATE [ 9 , 10 , 11 , 12 ]. Several others, such as Bicycle Therapeutics’ BT1718, BT5528 and BT8009, Cybrexa’s CBX-12 and Shenogen’s SNG1005, are undergoing clinical trials [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide–Drug Conjugates

Gomena

Vári

Oláh-Szabó

et al. 2023

IJMS

View full text Add to dashboard Cite

Targeted tumour therapy has proved to be an efficient alternative to overcome the limitations of conventional chemotherapy. Among several receptors upregulated in cancer cells, the gastrin-releasing peptide receptor (GRP-R) has recently emerged as a promising target for cancer imaging, diagnosing and treatment due to its overexpression on cancerous tissues such as breast, prostate, pancreatic and small-cell lung cancer. Herein, we report on the in vitro and in vivo selective delivery of the cytotoxic drug daunorubicin to prostate and breast cancer, by targeting GRP-R. Exploiting many bombesin analogues as homing peptides, including a newly developed peptide, we produced eleven daunorubicin-containing peptide–drug conjugates (PDCs), acting as drug delivery systems to safely reach the tumour environment. Two of our bioconjugates revealed remarkable anti-proliferative activity, an efficient uptake by all three tested human breast and prostate cancer cell lines, high stability in plasma and a prompt release of the drug-containing metabolite by lysosomal enzymes. Moreover, they revealed a safe profile and a consistent reduction of the tumour volume in vivo. In conclusion, we highlight the importance of GRP-R binding PDCs in targeted cancer therapy, with the possibility of further tailoring and optimisation.

show abstract

Peptide-Drug Conjugates: A New Hope for Cancer Management

Cited by 40 publications

References 221 publications

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

Current status of Cancer Nanotheranostics: Emerging strategies for cancer management

Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide–Drug Conjugates

Contact Info

Product

Resources

About